Table 1. Baseline Characteristics.
| IFX mono group (n=6) | ED+IFX group (n=14) | P-value | |
|---|---|---|---|
| Demographics | |||
| Sex (male/female) | 5/1 | 11/3 | 1.0000 |
| Age (yr) | 35.20±10.11 | 34.80±8.81 | 0.9202 |
| BMI (kg/m2) | 21.40±4.54 | 21.00±4.32 | 0.9044 |
| CDAI score | 210.70±17.47 | 211.00±60.78 | 0.1256 |
| Disease duration | 9.24±7.23 | 11.13±9.04 | 0.9680 |
| Disease location | 1.0000 | ||
| Ileitis (L1) | 1 (16.7) | 3 (21.4) | |
| Ileocolitis (L2) | 5 (83.3) | 11 (78.6) | |
| Perianal lesion | 1.0000 | ||
| Yes | 2 (33.3) | 4 (28.6) | |
| No | 4 (66.7) | 10 (71.4) | |
| Previous surgical resections | 1.0000 | ||
| 0 | 3 (50.0) | 6 (42.9) | |
| ≥1 | 3 (50.0) | 8 (57.1) | |
| Current smoking | 1 (16.7) | 2 (14.3) | 1.0000 |
| Medication at entry | |||
| Immunomodulator | 2 (33.3) | 4 (28.6) | 1.0000 |
| Steroid use | 0 | 0 | - |
| 5-ASA | 5 (83.3) | 12 (85.7) | 1.0000 |
| Concomitant medication | |||
| Immunomodulator | 2 (33.3) | 5 (35.7) | 1.0000 |
| Steroid use | 1 (16.7) | 0 | 0.3000 |
| 5-ASA | 5 (83.3) | 12 (85.7) | 1.0000 |
| CRP (mg/dL) | 0.34±0.26 | 0.74±0.81 | 0.5466 |
| Serum albumin (g/dL) | 3.88±0.32 | 3.91±0.63 | 0.4268 |
For calculation of the P-value, Wilcoxon's exact test was used for continuous values and Fisher exact test was used for categorical values. Statistical analyses were performed at a significance level of 0.05 (two-sided).
IFX, infliximab; ED, elemental diet; 5-ASA, 5-aminosalicylic acid.